Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Uveitis
Interventions
DRUG

Adalimumab plus different doses of oral glucocorticosteroid

A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER